Top U.S. Generic Blockbusters
News | 12 November 2012
The industry has talked nonstop for a couple of years about the patent loss of blockbuster drugs and the impact, earnings losses, job cuts, R&D retrenchment, job losses, CEO job losses. In fact, this year has been the worst, literally. Industry ...
Click on the link to read the full article at FiercePharma
(This link will open in a new window)
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
